146 related articles for article (PubMed ID: 34634528)
41. Development and validation of a high-performance liquid chromatography-tandem mass spectrometry assay quantifying vemurafenib in human plasma.
Nijenhuis CM; Rosing H; Schellens JH; Beijnen JH
J Pharm Biomed Anal; 2014 Jan; 88():630-5. PubMed ID: 24216282
[TBL] [Abstract][Full Text] [Related]
42. Investigation of anti-leishmanial efficacy of miltefosine and ketoconazole loaded on nanoniosomes.
Nazari-Vanani R; Vais RD; Sharifi F; Sattarahmady N; Karimian K; Motazedian MH; Heli H
Acta Trop; 2018 Sep; 185():69-76. PubMed ID: 29733808
[TBL] [Abstract][Full Text] [Related]
43. Generation of luciferase-expressing Leishmania infantum chagasi and assessment of miltefosine efficacy in infected hamsters through bioimaging.
Reimão JQ; Oliveira JC; Trinconi CT; Cotrim PC; Coelho AC; Uliana SR
PLoS Negl Trop Dis; 2015 Feb; 9(2):e0003556. PubMed ID: 25679212
[TBL] [Abstract][Full Text] [Related]
44. Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine.
van Andel L; Rosing H; Fudio S; Avilés P; Tibben MM; Gebretensae A; Schellens JHM; Beijnen JH
J Pharm Biomed Anal; 2017 Oct; 145():137-143. PubMed ID: 28662481
[TBL] [Abstract][Full Text] [Related]
45. Immune response following miltefosine therapy in a patient with post-kala-azar dermal leishmaniasis.
Ansari NA; Ramesh V; Salotra P
Trans R Soc Trop Med Hyg; 2008 Nov; 102(11):1160-2. PubMed ID: 18639311
[TBL] [Abstract][Full Text] [Related]
46. Assessing the Efficacy and Safety of Liposomal Amphotericin B and Miltefosine in Combination for Treatment of Post Kala-Azar Dermal Leishmaniasis.
Ramesh V; Dixit KK; Sharma N; Singh R; Salotra P
J Infect Dis; 2020 Feb; 221(4):608-617. PubMed ID: 31854451
[TBL] [Abstract][Full Text] [Related]
47. Quantitative determination of gracillin by HPLC-MS/MS after oral administration and its application to a pharmacokinetic study.
Zhang X; Xue X; Zhao J; Guo Z; Ito Y; Sun W
Steroids; 2016 Sep; 113():78-86. PubMed ID: 27394958
[TBL] [Abstract][Full Text] [Related]
48. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.
Aguiar MG; Pereira AM; Fernandes AP; Ferreira LA
Antimicrob Agents Chemother; 2010 Nov; 54(11):4699-704. PubMed ID: 20713665
[TBL] [Abstract][Full Text] [Related]
49. Quantitative determination of Orlistat (tetrahydrolipostatin, Ro 18-0647) in human plasma by high-performance liquid chromatography coupled with ion spray tandem mass spectrometry.
Bennett PK; Li YT; Edom R; Henion J
J Mass Spectrom; 1997 Jul; 32(7):739-49. PubMed ID: 9241856
[TBL] [Abstract][Full Text] [Related]
50. A novel UPLC-MS/MS method for sensitive quantitation of boldine in plasma, a potential anti-inflammatory agent: application to a pharmacokinetic study in rats.
Zeng RJ; Li Y; Chen JZ; Chou GX; Gao Y; Shao JW; Jia L; Wu SD; Wu SS
Biomed Chromatogr; 2015 Mar; 29(3):459-64. PubMed ID: 25065486
[TBL] [Abstract][Full Text] [Related]
51. Pharmacokinetics and disposition of miltefosine in healthy mice and hamsters experimentally infected with Leishmania infantum.
Jiménez-Antón MD; García-Calvo E; Gutiérrez C; Escribano MD; Kayali N; Luque-García JL; Olías-Molero AI; Corral MJ; Costi MP; Torrado JJ; Alunda JM
Eur J Pharm Sci; 2018 Aug; 121():281-286. PubMed ID: 29883726
[TBL] [Abstract][Full Text] [Related]
52. Miltefosine for new world cutaneous leishmaniasis.
Soto J; Arana BA; Toledo J; Rizzo N; Vega JC; Diaz A; Luz M; Gutierrez P; Arboleda M; Berman JD; Junge K; Engel J; Sindermann H
Clin Infect Dis; 2004 May; 38(9):1266-72. PubMed ID: 15127339
[TBL] [Abstract][Full Text] [Related]
53. Pharmacokinetic / pharmacodynamic relationships of liposomal amphotericin B and miltefosine in experimental visceral leishmaniasis.
Voak AA; Harris A; Coteron-Lopez JM; Angulo-Barturen I; Ferrer-Bazaga S; Croft SL; Seifert K
PLoS Negl Trop Dis; 2021 Mar; 15(3):e0009013. PubMed ID: 33651812
[TBL] [Abstract][Full Text] [Related]
54. Simultaneous Determination of Purpurin, Munjistin and Mollugin in Rat Plasma by Ultra High Performance Liquid Chromatography-Tandem Mass Spectrometry: Application to a Pharmacokinetic Study after Oral Administration of Rubia cordifolia L. Extract.
Gao M; Yang J; Wang Z; Yang B; Kuang H; Liu L; Wang L; Yang C
Molecules; 2016 Jun; 21(6):. PubMed ID: 27258244
[TBL] [Abstract][Full Text] [Related]
55. [Determination of eight environmental phenols in human urine samples by high-throughput solid-phase extraction-ultra-performance liquid chromatography-tandem mass spectrometry].
Lin X; Qiu T; Zhang X; Hu X; Yang Y; Zhu Y
Se Pu; 2020 Dec; 38(12):1456-1464. PubMed ID: 34213261
[TBL] [Abstract][Full Text] [Related]
56. Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.
Bhandari V; Kulshrestha A; Deep DK; Stark O; Prajapati VK; Ramesh V; Sundar S; Schonian G; Dujardin JC; Salotra P
PLoS Negl Trop Dis; 2012; 6(5):e1657. PubMed ID: 22629478
[TBL] [Abstract][Full Text] [Related]
57. Determination of crizotinib in human and mouse plasma by liquid chromatography electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS).
Roberts MS; Turner DC; Broniscer A; Stewart CF
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jun; 960():151-7. PubMed ID: 24811158
[TBL] [Abstract][Full Text] [Related]
58. Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
Dorlo TP; Balasegaram M; Beijnen JH; de Vries PJ
J Antimicrob Chemother; 2012 Nov; 67(11):2576-97. PubMed ID: 22833634
[TBL] [Abstract][Full Text] [Related]
59. Simple implementation of muscle tissue into routine workflow of blood analysis in forensic cases - A validated method for quantification of 29 drugs in postmortem blood and muscle samples by UHPLC-MS/MS.
Hansen SL; Nielsen MKK; Linnet K; Rasmussen BS
Forensic Sci Int; 2021 Aug; 325():110901. PubMed ID: 34245938
[TBL] [Abstract][Full Text] [Related]
60. Simultaneous quantification of 19 analytes in breast milk by liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Monfort A; Jutras M; Martin B; Boucoiran I; Ferreira E; Leclair G
J Pharm Biomed Anal; 2021 Sep; 204():114236. PubMed ID: 34273657
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
